IRB #

STUDY00020357

Title

[NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Principal Investigator

Charles Lopez

Study Purpose

The purpose of this study is to compare the effects of adding the drug nab-paclitaxel to the standard of care drugs cisplatin and gemcitabine versus cisplatin and gemcitabine alone.

Medical Condition(s)

biliary tract cancer
intrahepatic cholangiocarcinoma
extrahepatic cholangiocarcinoma
gallbladder cancer

Eligibility Criteria

- Participants must have locally advanced or metastatic intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Participants will be followed for up to 3 years after study entry

Minors Included

No

Contact

Knight Information Line - trials@ohsu.edu or 503-494-1080

Sponsor

SWOG

Recruitment End

08/02/2027

Compensation Provided

No


Go Back